| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/29/2005 | US6872702 Cyclic peptide; antitumor agents; antiinflammatory agents; tissue remodeling |
| 03/29/2005 | US6872701 Glycopeptide phosphonate derivatives |
| 03/29/2005 | US6872700 Methods for glucagon suppression |
| 03/29/2005 | US6872699 Truncated Flk-1 receptor protein, methods of use and a recombinant vector containing a nucleotide encoding the truncated Flk-1 protein |
| 03/29/2005 | US6872698 Treating or preventing nerve cell death or degeneration by administering GDF-1 or a nucleic acid encoding GDF-1; especially combined with neurotrophin-3 or nucleic acid encoding neurotrophin-3. |
| 03/29/2005 | US6872568 Death domain containing receptor 5 antibodies |
| 03/29/2005 | US6872560 Human hydrolytic enzymes |
| 03/29/2005 | US6872558 Heparanase-2 a member of the heparanase protein family |
| 03/29/2005 | US6872557 Gene encoding novel human secretory phospholipase A2 |
| 03/29/2005 | US6872554 For therapy of Alzheimer's disease; immunization |
| 03/29/2005 | US6872551 Rapidly cleavable sumo fusion protein expression system for difficult to express proteins |
| 03/29/2005 | US6872548 Polypeptide for use in animal models associated with human therapeutics |
| 03/29/2005 | US6872520 Peptide for use in the detection of viral infection and diseases |
| 03/29/2005 | US6872404 Ophthalmologic uses of protein C |
| 03/29/2005 | US6872398 Conjugate vaccine against gram-negative bacterial infections |
| 03/29/2005 | US6872397 Administering to the patient a therapeutical amount of botulinum toxin of a selected serotype until patient experiences loss of clinical response to the toxin and then administering another botulinum toxin of a different serotype |
| 03/29/2005 | US6872392 Humanized antibodies |
| 03/29/2005 | US6872391 Nucleotide sequences coding polypeptide for use in the treatment of eating disorders |
| 03/29/2005 | US6872390 Local anesthetic methods and kits |
| 03/29/2005 | US6872388 For prevention of plant diseases; cell-free extracts |
| 03/29/2005 | US6872385 Adjuvant preparation for the induction of specific immunity |
| 03/29/2005 | US6872384 Comprises anionic microgel for treatment of corneal wounds |
| 03/29/2005 | CA2425745C Expression of exogenous polynucleotide sequences in a vertebrate |
| 03/29/2005 | CA2323506C Mammalian blood loss-induced gene, kd312 |
| 03/29/2005 | CA2195745C Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens |
| 03/29/2005 | CA2180950C Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof |
| 03/29/2005 | CA2170772C Use of nitric oxide-adducts to prevent thrombosis on artificial and vascular surfaces |
| 03/29/2005 | CA2137271C Apparatus for obtaining a supernatant of activited thrombocytes, process for said apparatus and supernatant thereof |
| 03/29/2005 | CA2108699C Method of purification of amylase, purified amylase so obtained and uses of purified amylase |
| 03/29/2005 | CA2065346C Tumor necrosis factor-.alpha. and-.beta. receptors |
| 03/29/2005 | CA2049287C Expression of exogenous polynucleotide sequences in a vertebrate |
| 03/29/2005 | CA1341477C Method of reducing immunoglobulin e responses |
| 03/26/2005 | CA2441695A1 Regulation of matrix metalloproteinases by psp94 family members |
| 03/24/2005 | WO2005026741A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |
| 03/24/2005 | WO2005026733A1 Method and device for detecting feline immunodeficiency virus |
| 03/24/2005 | WO2005026725A1 Diagnostics and therapeutics for diseases associated with organic antion transporter slc22a8 (slc22a8) |
| 03/24/2005 | WO2005026724A2 Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a5 (slc22a5) |
| 03/24/2005 | WO2005026723A1 Diagnostics and therapeutics for diseases associated with organic cation transporter slc22a1 (slc22a1) |
| 03/24/2005 | WO2005026388A2 The use of eukaryotic genes affecting chromatin separation for diagnosis and treatment of proliferative diseases |
| 03/24/2005 | WO2005026362A2 Lymphatic and blood endothelial cell genes |
| 03/24/2005 | WO2005026361A1 Soluble ectodomain fragments of met and uses thereof |
| 03/24/2005 | WO2005026357A1 Antisense oligonucleotides for prevention of metastasis formation of cancer cells |
| 03/24/2005 | WO2005026341A2 Plasminogen activators having reduced lysine binding capacity |
| 03/24/2005 | WO2005026323A2 Stationary phases and a purification process using the stationary phases |
| 03/24/2005 | WO2005026315A2 Method for producing insulin from a natural source and insulin |
| 03/24/2005 | WO2005026269A1 Microorganism coating components, coatings, and coated surfaces |
| 03/24/2005 | WO2005026207A2 Adipocyte complement related protein zacrp12 |
| 03/24/2005 | WO2005026206A2 Vegf-induced genes and their therapeutic use |
| 03/24/2005 | WO2005026204A2 Synthetic antimicrobial polypeptides |
| 03/24/2005 | WO2005026202A1 Compositions comprising a fragment of the herpesviral protein vp22 for delivery of substances to cells |
| 03/24/2005 | WO2005026195A1 Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive aspergillosis |
| 03/24/2005 | WO2005026194A2 Granulysin peptides and methods of use thereof |
| 03/24/2005 | WO2005026192A2 Hpv cd8+ t-cell epitopes |
| 03/24/2005 | WO2005026170A2 Uses of neuronal pannexins for therapy and diagnosis in mammals |
| 03/24/2005 | WO2005025624A2 The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases |
| 03/24/2005 | WO2005025619A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 03/24/2005 | WO2005025611A1 Inhibitors of pace4 for the treatment of arthritis |
| 03/24/2005 | WO2005025610A1 Use of markk or markk antagonists for the treatment of pathologies characterised by increased or reduced phosphorylation of mark or tau protein |
| 03/24/2005 | WO2005025609A1 Lactoferrin material composition |
| 03/24/2005 | WO2005025608A1 Ifn-ϝ for treatment of diseases associated with malfunction of the nod2 gene |
| 03/24/2005 | WO2005025607A1 Methods of stimulating innate immunity using cationic peptides |
| 03/24/2005 | WO2005025606A1 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 03/24/2005 | WO2005025605A1 Remedy and therapeutic method for periodontal diseases and pulpal diseases |
| 03/24/2005 | WO2005025604A2 Use of hmgb and hmgb fragments to decrease specific immune response |
| 03/24/2005 | WO2005025602A1 METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH |
| 03/24/2005 | WO2005025601A1 Follistatin isoforms and uses thereof |
| 03/24/2005 | WO2005025600A1 Drug inhibiting mobilization of adhesive cells into peripheral blood |
| 03/24/2005 | WO2005025599A1 A glycopeptide composition with improved antibiotic activity |
| 03/24/2005 | WO2005025598A1 Antibacterial drug for propionibacterium acnes |
| 03/24/2005 | WO2005025597A1 Peptides that promote complement activation |
| 03/24/2005 | WO2005025596A1 Glatiramer acetate for use as an immuno-modulatory agent |
| 03/24/2005 | WO2005025595A2 Injectable calcium phosphate solid rods and pastes for delivery of osteogenic proteins |
| 03/24/2005 | WO2005025594A1 Method to enhance hematopoiesis |
| 03/24/2005 | WO2005025593A2 Treatment of inflammatory respiratory diseases |
| 03/24/2005 | WO2005025592A2 In vivo modulation of neuronal transport |
| 03/24/2005 | WO2005025591A2 CASPASE DERIVED CARDs |
| 03/24/2005 | WO2005025590A2 Use of a dg280 protein product for preventing and treating metabolic disorders |
| 03/24/2005 | WO2005025567A1 Benzothiazole derivatives for the treatment of diabetes |
| 03/24/2005 | WO2005025553A2 Treatment of disorders of nervous systemsystem with fty720 |
| 03/24/2005 | WO2005025552A2 Protein binding compounds |
| 03/24/2005 | WO2005025548A1 Topical preparations comprising a hydrophilic carrier and a silicone matrix |
| 03/24/2005 | WO2005025543A2 Polymer-based sustained release device and method for preparation |
| 03/24/2005 | WO2005025538A1 Composition for medical use containing sugar chain-containing chitosan derivative and glycosaminoglycan |
| 03/24/2005 | WO2005025517A2 Animal model for protease activity and liver damage |
| 03/24/2005 | WO2005025514A2 Compounds that modulate neuronal growth and their uses |
| 03/24/2005 | WO2005025503A2 A composition and method of treatment for urogenital conditions |
| 03/24/2005 | WO2005025501A2 Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer |
| 03/24/2005 | WO2005025499A2 Hydrophobic drug compositions containing reconstitution enhancer |
| 03/24/2005 | WO2005025497A2 Hpv cd8+ t-cell epitopes |
| 03/24/2005 | WO2005025494A2 Vaccine immunotherapy for immune suppressed patients |
| 03/24/2005 | WO2005025335A1 Milk fractions and milk preparations for treating and/or preventing cox-2 mediated diseases |
| 03/24/2005 | WO2005016963A3 Heparin binding veger-3 ligands |
| 03/24/2005 | WO2005012355B1 Bioactive peptides derived from the proteins of egg white by means of enzymatic hydrolysis |
| 03/24/2005 | WO2005012333A3 Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof |
| 03/24/2005 | WO2005012328A3 Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof |
| 03/24/2005 | WO2005011640A3 Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof |
| 03/24/2005 | WO2005011612A3 Alpha 4 beta 2 delta gaba-a receptors as a strategy for pms and alcoholism |
| 03/24/2005 | WO2005009498A3 Decellularized bone marrow extracellular matrix |
| 03/24/2005 | WO2005007855A3 RNA INTERFERENCE MEDIATED INHIBITION OF B7-H1 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 03/24/2005 | WO2005005477A3 Stabilised insulin compositions |